关键词: OPRM1 A118G, 舒芬太尼, 基因多态性

Abstract: ［Abstract］ Objective To investigate the analgesic effect of OPRM1 A118G gene polymorphism on sufentanil in patients with hilar cholangiocarcinoma. Method Fifty patients scheduled for elective hilar cholangiocarcinoma operation underwent combined intravenous and inhalationanesthesia. Patient-controlled analgesia（PCA） with sufentanil injection （2.00 μg·kg-1·h-1） was used for post-operative analgesia. The total dosage of sufentanil and adverse events were recorded at 24h and 48h after operation administration. The OPRM1 A118G gene type were detected. Results Among 55 patients， the proportion of AA，AG and GG genotype was 44%， 40% and 16%，respectively. Distribution frequency of A and G allele were 64% and 36%. The 24 h dosage of sufentanil in AG and GG genotype patients were both higher than AA genotype patients 60.02±21.45 μg vs 47.12±11.39 μg， P=0.040，77.93±31.87 μg vs 47.12±11.39 μg， P=0.031. At 48 h， the dosage of sufentanil in AG and GG genotype patients were also significantly higher than AA genotype patients103.92±27.66 μg vs 88.76±19.27 μg， P=0.009； 121.90±29.88 μg vs 88.76±19.27 μg， P=0.002）. There was no significant difference in adverse events between three groups （P>0.05）. Conclusion The analgesic efficacy of sufentanil was affected with OPRM1 A118G gene polymorphism in patients with hilar cholangiocarcinoma.

Key words: polymorphism, OPRM1 A118G, sufentanil